is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. Additionally, he is the Director of the Myeloma, Waldenström's, and Amyloidosis Program at UTSW’s Harold C. Simmons Comprehensive Cancer Center, where he also leads the Hematologic Malignancies and Cellular Therapy Clinical Research Program. He is also the Co-Director of the Phase I Clinical Trial Research Program and of the Cellular Immunotherapy and Autologous Stem Cell Transplant Program. Dr. Anderson specializes in the treatment of plasma cell disorders such as multiple myeloma, Waldenström's macroglobulinemia, amyloidosis, and other gammopathies. He treats patients with these diseases at all phases and stages, from diagnosis through stem cell transplant and relapse, and he has a particular interest in CAR T-cell therapy and clinical trials of immunotherapy. He runs an active clinical trial research program that has been a lead enrolling site for many practice-changing myeloma clinical trials (including KarMMa, GRIFFIN, and DETERMINATION), which has helped his program become a world-class center of excellence for plasma cell disorders. In 2000, Dr. Anderson earned both his medical degree at UT Health Science Center at Houston and his doctoral degree in immunology from MD Anderson Cancer Center and the UTHSC Houston Graduate School of Biomedical Sciences. He completed an internship and residency in internal medicine at the Mayo Clinic, followed by a fellowship in medical oncology at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center, where he later served as a research associate for two years before joining the UT Southwestern faculty in 2008. He is certified is a Diplomate of both the American Board of Internal Medicine and its Subspecialty Board of Medical Oncology and is a Fellow of the American College of Physicians. In addition, Dr. Anderson is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Society for Transplantation and Cellular Therapy (ASTCT), the International Myeloma Society, the International Society of Amyloidosis, and the Texas Medical Association. He has been named a Texas Monthly Super Doctor every year since 2018 and a D Magazine Best Doctor every year since 2021. He serves on the NCCN Guidelines Panel for plasma cell disorders and on the ASTCT’s Cellular Therapy Committee. Dr. Anderson’s research interests include cancer immunotherapy, multiple myeloma, and chimeric antigen receptor T-cell (CAR T) therapy. His research has been funded by the American Cancer Society, the National Institutes of Health, the American Society of Clinical Oncology, and the Multiple Myeloma Research Foundation.

Dr. Khan earned his medical degree with special distinction at the University of Michigan in Ann Arbor, Michigan, while also obtaining a master’s degree in public health from Harvard University. He performed a residency in internal medicine at the Cleveland Clinic and Lerner College of Medicine in Cleveland, Ohio. After serving as a hospitalist at Massachusetts General Hospital and an instructor at Harvard Medical School and concurrently obtaining a master's degree in epidemiology from Columbia University, he gained advanced training in hematology and oncology through a fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. He is currently an Assistant Professor of Medicine and Public Health at UT Southwestern Medical Center where he serves as the Director of Myeloma Epidemiology Research and Clinical Director of the Monoclonal Gammopathy Precursor Clinic.

is a Clinical Pharmacy Specialist in the Division of Hematology and Oncology at UT Southwestern Medical Center. He holds a bachelor's degree in pharmaceutical sciences from the University of Mississippi in Oxford. He then completed his doctor of pharmacy at the University of Mississippi. Dr. Hinojosa joined the UT Southwestern faculty in 2022.

is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in multiple myeloma and other plasma cell dyscrasias, developing cellular therapy such as CAR T-cells with or without transplant, and immunotherapy. Dr. Afrough earned her medical degree at Tabriz University of Medical Sciences in Iran and completed a residency in internal medicine at St. Agnes Hospital in Baltimore. She received advanced training through a hematology and oncology fellowship at Baylor College of Medicine and a stem cell transplantation and cellular therapy fellowship at the University of Texas MD Anderson Cancer Center. Certified by the American Board of Internal Medicine in medical oncology and hematology, she joined the UT Southwestern faculty in 2021. Dr. Afrough’s clinical research is focused on improving the therapy and outcome of patients with plasma cell disorders. She is particularly interested in developing novel therapeutic approaches, including adoptive cell therapy to improve the safety and efficacy of therapies in patients with these disorders. She has published numerous academic articles and delivered multiple presentations. She is a member of several professional associations, including the American Society of Clinical Oncology, the American Society of Hematology, the American Society for Transplantation and Cellular Therapy, and the International Myeloma Society. In 2019, Dr. Afrough received the Cancer Prevention and Research Institute of Texas (CPRIT) Training Award from the Baylor College of Medicine Comprehensive Cancer Training Program.

received his Bachelor of Science in psychology, graduating magna cum laude, from Washington & Lee University in Lexington, VA. He earned his medical degree from the University of Texas Southwestern Medical Center in Dallas, TX. He completed his internship and residency in internal medicine and then a fellowship in hematology and oncology at UT Southwestern in 1999. Before joining Texas Oncology in 2001, Dr. Berryman was an assistant professor of internal medicine, division of hematology and medical oncology, at the Harold C. Simmons Cancer Center at UT Southwestern. He was also an attending physician in the emergency department at the Dallas VA Medical Center. Dr. Berryman is currently the Director for Outreach and Clinics for the Blood and Marrow Transplantation Services at Baylor University Medical Center, part of Baylor Scott & White Health. He is the principal investigator and the co-investigator for numerous research trials and has authored and coauthored many articles in peer reviewed journals. Dr. Berryman is married and is the father of two daughters.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.